SynCo To Make Acromegaly Drug for Syntaxin

SynCo Bio Partners B.V. has signed an agreement to produce Syntaxin's novel drug candidate SXN101959.

SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals, announced this week that it has inked a deal with Syntaxin, a biotechnology company specialising in innovative biopharmaceutical therapies for cell secretion control, to produce Syntaxin's novel drug candidate SXN101959.

Syntaxin is developing SXN101959 for the therapeutic treatment of acromegaly as a primary indication. SynCo will assist Syntaxin in scale-up and manufacture of multiple batches of bulk drug substance and drug product of SXN101959 for non-clinical, Phase I and Phase II clinical trials.

In acromegaly, hypersecretion of growth hormone usually occurs from a benign